Contemporary Amperex Technology
300750
Kweichow Moutai
600519
Jiangsu Hengrui Pharmaceuticals
600276
4
Sichuan Chengfei Integration Technology Corp.Ltd.
002190
5
BYD Company Limited
002594
CN Stock MarketDetailed Quotes
002022 Shanghai Kehua Bio-engineering
- 5.99
- +0.01+0.17%
Market Closed May 19 15:00 CST
3.08BMarket Cap-4.63P/E (TTM)
6.01High5.96Low54.58KlotVolume5.96Open5.98Pre Close32.67MTurnover1.06%Turnover RatioLossP/E (Static)514.32MShares7.4052wk High0.94P/B3.08BFloat Cap4.8852wk Low6.58Limit Up514.24MShs Float62.49Historical High5.38Limit Down0.84%Amplitude-1.78Historical Low--Dividend TTM5.99Avg Price30.35KlotAsk--Div Yield TTM100Lot Size24.01KlotBid
Shanghai Kehua Bio-engineering News
Kehua Biotech: Report for the first quarter of 2025
Express News | Shanghai Kehua Bio-engineering: Net loss of 53.2598 million yuan in the first quarter of 2025.
Kehua Biotech: 2024 Annual Report
Kehua Biotech: 2024 Annual Report Summary
Express News | Shanghai Kehua Bio-engineering: The fully automated chemiluminescence immunoassay analyzer has obtained the medical instruments registration certificate.
Shanghai Kehua Bio-engineering (002022.SZ): plans to invest in a production base for Medical Devices and testing reagents, as well as a medical industry incubation and innovation center project in the Xi'an Economic and Technological Development Zone.
On April 8, Gelonghui reported that Shanghai Kehua Bio-engineering (002022.SZ) announced that on April 8, 2025, the company signed the "Investment Cooperation Agreement for the Medical Devices and Testing Reagents Production Base and Medical Industry Incubation Innovation Center Project" with the Management Committee of the Xi'an Economic and Technological Development Zone. The company plans to invest in the medical devices and testing reagents production base and medical industry incubation innovation center project in the Xi'an Economic and Technological Development Zone, with a project area of approximately 90 acres, divided into two phases: Phase one is for the medical devices and testing reagents production base project, taking up about 50 acres, mainly producing chemiluminescence products, medical devices and testing reagents; Phase two is for the medical industry.
Express News | Shanghai Kehua Bio-engineering: Signed an investment cooperation agreement.
Express News | Shanghai Kehua Bio-engineering: Senior Vice President Ms. CHEN CHAO has resigned for personal reasons.
Express News | Shanghai Kehua Bio-engineering: The company's product, the hepatitis C virus (HCV) nucleic acid test kit (PCR-fluorescent method), has obtained the medical instruments registration certificate.
Express News | Shanghai Kehua Bio-engineering: Subsidiary obtained hepatitis C reagent registration certificate.
Express News | Waters and Shanghai Kehua Bio-engineering jointly launched two sets of domestic liquid chromatography-mass spectrometry IVD systems, which have been approved by the drug regulatory authority in China.
Kehua Biotech: 2024 Annual Performance Forecast
Express News | Shanghai Kehua Bio-engineering: Expected net income loss of 0.53 billion yuan – 0.65 billion yuan in 2024.
Shanghai Kehua Bio-engineering (002022.SZ) has been approved by the National Medical Products Administration: new test kit for Helicobacter pylori antibody detection.
On January 1, Gelonghui reported that Shanghai Kehua Bio-engineering (002022.SZ) announced that it recently received the medical instruments registration certificate issued by the National Medical Products Administration (in vitro diagnostic reagents). The specific product is "Helicobacter pylori antibody detection kit (latex immunoturbidimetry method)", with registration certificate number National Medical Device Approval 20243402655, valid from December 30, 2024, to December 29, 2029. This product is used for the qualitative detection of Helicobacter pylori antibodies in human serum and plasma samples.
Kehua Tech Recognized in BNEF's Latest Bankability Survey
Kehua Ranked No.4 in the Global Modular UPS Market Share for Two Consecutive Years
Shanghai Kehua Bio-Engineering, Subsidiaries to Invest 68 Million Yuan for New Unit
Shanghai Kehua Bio-engineering (002022.SZ) plans to establish a subsidiary to undertake the high-performance diagnostic medical instruments innovation center project in Shaanxi Province.
Shanghai kehua bio-engineering (002022.SZ) announced the commencement of the Shaanxi Province High-Performance Diagnostic Medical Instruments Innovation Center project...
Express News | shanghai kehua bio-engineering: plans to establish a subsidiary with 68 million yuan.
shanghai kehua bio-engineering (002022.SZ): not involved in chip R&D business
gelonhui November 28th | shanghai kehua bio-engineering (002022.SZ) stated on the investor interaction platform that the company's main business is the research and development, production, and sales of in vitro diagnostic reagents and medical testing instruments. The company is not involved in chip R&D business.
Market Insights
Investment Course
Essential Crypto strategies to learn for beginners.
Beginner's Guide: Understand how to invest in Crypto in 3 minutes.
Crypto (Cryptos) is, in simple terms, a virtual currency based on cryptographic principles to ensure transaction security. Unlike the currencies we use daily, C
How to Trade Crypto on Futubull
Step 1: Activate the Cryptos Account. Comprehensive Account > More > Account Management > Activate Trading Products > Select [Cryptos] to start the process. Not
A comprehensive review of crypto history
Have you heard the latest about Bitcoin? In 2024 H1, its value once surged by 68% . As the largest and most well-known cryptocurrency, Bitcoin has increased in